S0931

Kidney

Roudebush VA Medical Center

• Roudebush VA Medical Center

• Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)
  Synold TW;Plets M;Tangen CM;Heath EI;Palapattu GS;Mack PC;Stein MN;Meng MV;Lara P;Vogelzang NJ;Thompson IM;Ryan CW;
• Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
  Ryan CW;Tangen CM;Heath EI;Stein MN;Meng MV;Alva AS;Pal SK;Puzanov I;Clark JI;Choueiri TK;Agarwal N;Uzzo RG;Haas NB;Synold TW;Plets M;Vaishampayan UN;Shuch BM;Thompson IM;Lara PN;
• Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial
  Gulati S;Tangen C;Ryan CW;Vaishampayan UN;Shuch BM;Barata PC;Pruthi DK;Bergerot CD;Tripathi A;Lerner SP;Thompson IM;Lara PN;Pal SK;